NASDAQ OMX

Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu(TM) Vaccine

Dela
  • RSV F Vaccine informational analysis completed in fourth quarter of 2017
  • RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees
  • Filing of RSV F Vaccine BLA anticipated by late 2019
  • NanoFlu Vaccine data package to be completed and released in February 2018

GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)).

RSV F Vaccine for Infants via Maternal Immunization

"Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result, we are accelerating our Phase 3 trial enrollment into 2018. Our maternal immunization program is supported by an $89 million grant from the Bill and Melinda Gates Foundation and has also been granted Fast Track designation by the U.S. Food and Drug Administration," said Stanley C. Erck, President and CEO. "We have enrolled over 3,000 volunteers to date and anticipate that the current pace of enrollment would trigger an interim analysis in mid-2018, with an expected Phase 3 primary endpoint readout in early 2019. This timing would allow us to submit a biologics license application (BLA) by the end of 2019."

NanoFlu Vaccine

A number of key scientific developments regarding influenza vaccines for the current season have occurred and relate to our NanoFlu program, including:

  • A November 29, 2017, editorial in the New England Journal of Medicine 1 detailed public health concerns related to the poor efficacy of existing seasonal influenza vaccines that is due, in part, to genetic changes or drift in the hemagglutinin (HA) protein, leading to low vaccine efficacy
  • Based on analyses from the Southern Hemisphere, the effectiveness of the seasonal influenza vaccine was as low as 10% for the A(H3N2) strain2
  • A November 6, 2017, Proceedings of the National Academy of Sciences 3 publication identified that the circulating influenza A(H3N2) virus contains an HA structure that has been lost in the corresponding vaccine strain during adaptation to be grown in eggs ("egg-adapted") as part of the typical seasonal influenza vaccine manufacturing process, which, in turn, affects vaccine efficacy for egg-based vaccines
  • Novavax' NanoFlu vaccine candidate is designed specifically to address these challenges
  • The wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability
  • Therefore, a complete Phase 1/2 data package expected in February 2018

"Recent information published presents both an opportunity and a challenge for our NanoFlu Vaccine program. First, we have the unique opportunity to determine whether our recombinant, adjuvanted NanoFlu vaccine can address egg-adapted virus mismatch. We can also observe whether our vaccine-induced antibodies can neutralize circulating viruses with antigenic drift in humans, as we demonstrated in our ferret study earlier this year," said Greg Glenn, M.D., President, R&D. "Our team has been able to optimize our assays to address this challenge and we expect to present NanoFlu immunogenicity data that includes HA inhibition and microneutralization assays comparing wild-type virus and egg-based reagents."

About RSV

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively4. In the US, RSV is the leading cause of hospitalization of infants5. Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common6,7. Currently, there is no approved RSV vaccine available.

About Influenza

Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as pediatrics and older adults, but also in the general population largely because of infection by unique strains of influenza for which most humans have not developed protective antibodies. An estimated one million deaths each year are attributed to influenza8. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in the 2012-2013 season to $5.3 billion by the 2021-2022 season9.

About Fast Track

The Fast Track Drug Development Program was established under the FDA Modernization Act of 1997. A Fast Track designation is intended for products that treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for such diseases or conditions. The program is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. Specifically, Fast Track designation facilitates meetings to discuss all aspects of development to support licensure and it provides the opportunity to submit sections of a Biologics License Application (BLA) on a rolling basis as data become available, which permits the FDA to review modules of the BLA as they are received instead of waiting for the entire BLA submission. In addition, priority review (6 month review versus standard 10 month review) is a potential benefit that may be available to Novavax' RSV F vaccine in the future.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

References

1. Paules, C. I. et al. Chasing seasonal influenza - The need for a universal influenza vaccine. NEJM, 2017. DOI: 10.1056/NEJMp1714916.
2. Sullivan, S. G. et al. Low interim influenza vaccines effectiveness, Australia, 1 May to 24 September 2017, Eurosurveillance, 2017, 22(43): pii=17-00707. https://doi.org/10.2807/1560-7917.ES.2017.22.43.17-007073. Zost, S.J., et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. PNAS, 2017, 12578-12583, doi: 10.1073/pnas.1712377114.
4. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010; 375: 1545-1555.
5. Hall, C.B. et al. Respiratory Syncytial Virus-Associated hospitalizations Among Children Less Than 24 Months of Age. Pediatrics, 2013; 132(2): E341-348.
6. Glezen, W.P. et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 1986; 140:543-546.
7. Glenn GM, et al. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine, 2015, http://dx.doi.org/10.1016/j.vaccine.2015.08.039.
8. Resolution of the World Health Assembly. (2003) WHA56.19.28
9. Influenza Vaccines Forecasts. Datamonitor (2013)

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2016 and the Quarterly Report on Form 10-Q for the period ended September 30, 2017, both as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contact:         

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir@novavax.com
240-268-2000
               
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com 
maggie.beller@russopartnersllc.com
212-845-4271




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00Pressmeddelande

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut

SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00Pressmeddelande

Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and

Standard Lithium Completes Successful Gravity Geophysical Survey at Cadiz Dry Lake, California Lithium Project19.4.2018 11:30Pressmeddelande

VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that Hasbrouck Geophysics Inc. has successfully completed a large-scale gravity geophysical survey at the Company's Cadiz Dry Lake Project, in the Mojave area of California. The Cadiz Dry Lake Property is located approximately 20 km southeast of the Company's Bristol Dry Lake Property and is currently permitted for brine extraction and processing activities. The work has defined an infilled basin with a maximum depth of just over 700 m beneath the Project area. Dr. Andy Robinson, COO and President of Standard Lithium commented: "The results from this high quality geophysical survey are very encouraging. This work has defined a closed basin with infill deposits that are known to host lithium brines, based on preliminary sampling of extraction wells operated by the permitted producer. Standard Lithium's excellent relations

ConnectWise Launches Unite, Its Cloud Monitoring, Management and Billing Solution19.4.2018 10:03Pressmeddelande

IT Nation Europe keynote also reveals plans for an advanced security dashboard and growing the company's international footprint LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- ConnectWise CEO Arnie Bellini told an audience of more than 350 at the company's annual IT Nation Europe conference in London that ConnectWise Unite is now available to technology teams across the globe. Unite is a cloud management solution that gives technology teams the ability to manage, monitor and bill a broad range of cloud-based solutions through a single pane of glass and in their own currency. "Technology teams typically take advantage of a broad range of cloud solutions to meet their customers' unique needs. What we've done with ConnectWise Unite is give our partners the ability to access these disparate solutions from a single pane of glass and greatly simplify the complexity that comes from dealing with the growing number of solutions they use," Bellini said. He explained that connecting the ecosystem sea

D4t4 Solutions Announces Latest Celebrus Release19.4.2018 10:00Pressmeddelande

Celebrus Advances Customer Data Platform Leadership Further with New Product Features Latest update consolidates Celebrus as enterprise CDP of choice for banking and insurance sectors Integration with Adobe Experience Cloud augments leading digital marketing platform with streaming customer data New Audience Segmentation feature enables advanced targeting of individuals even when they have left a site or app Latest connector supports creation of Custom Audiences in Google and Facebook Hadoop capabilities extended with enhanced support for Hive open-source data warehouse SUNBURY-ON-THAMES, United Kingdom, April 19, 2018 (GLOBE NEWSWIRE) -- D4t4 Solutions Plc has announced general availability for the latest release of its leading Celebrus Customer Data Platform (CDP). Continuing its commitment to creating the industry's most advanced unified system for customer data, Version 8 Update 19 delivers a host of new features that broaden the appeal of Celebrus to enterprises focused on deepeni

Leading European Media Company De Persgroep Selects Aria Systems for Digital Transformation19.4.2018 09:08Pressmeddelande

Aria's cloud billing and monetization platform will manage millions of subscriptions across dozens of media properties SAN FRANCISCO and ASSE, Belgium, April 19, 2018 (GLOBE NEWSWIRE) -- Aria Systems, the leader in helping enterprises grow subscription- and usage-based revenue, today announced that De Persgroep, the leading news media publisher in the Netherlands, Belgium and Denmark, is deploying Aria's platform to enable their digital growth strategy. With Aria the company will accelerate time to market for new products, increase subscriber growth and retention, and improve the overall customer experience. Among the publications included in this digital strategy are 18 newspapers and periodicals across the portfolios of De Persgroep Publishing, De Persgroep Nederland, and Berlingske Media. De Persgroep selected Aria's cloud-based billing and monetization platform to support the subscription management processes for all news media and magazine subscriptions. The company can now manage

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum